

Theodore A Gooley

List of Publications by Year
in descending order

Source: <https://exaly.com/author-pdf/6311079/publications.pdf>

Version: 2024-02-01

164
papers

14,757
citations

25034
57
h-index

18647
119
g-index

165
all docs

165
docs citations

165
times ranked

11577
citing authors

#	ARTICLE	IF	CITATIONS
1	CD19 CARâ€T cells of defined CD4+:CD8+ composition in adult B cell ALL patients. Journal of Clinical Investigation, 2016, 126, 2123-2138.	8.2	1,657
2	Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood, 2001, 97, 3390-3400.	1.4	1,306
3	Bone Marrow Transplants from Unrelated Donors for Patients with Chronic Myeloid Leukemia. New England Journal of Medicine, 1998, 338, 962-968.	27.0	602
4	Microchimerism and HLA-compatible relationships of pregnancy in scleroderma. Lancet, The, 1998, 351, 559-562.	13.7	574
5	Optimizing Outcome After Unrelated Marrow Transplantation by Comprehensive Matching of HLA Class I and II Alleles in the Donor and Recipient. Blood, 1998, 92, 3515-3520.	1.4	442
6	Generation of T-Cell Immunity to the HER-2/neu Protein After Active Immunization With HER-2/neu Peptideâ€Based Vaccines. Journal of Clinical Oncology, 2002, 20, 2624-2632.	1.6	411
7	Relation of an Interleukin-10 Promoter Polymorphism to Graft-versus-Host Disease and Survival after Hematopoietic-Cell Transplantation. New England Journal of Medicine, 2003, 349, 2201-2210.	27.0	360
8	Cord-Blood Transplantation in Patients with Minimal Residual Disease. New England Journal of Medicine, 2016, 375, 944-953.	27.0	352
9	Cyclophosphamide metabolism, liver toxicity, and mortality following hematopoietic stem cell transplantation. Blood, 2003, 101, 2043-2048.	1.4	323
10	Parainfluenza virus infections after hematopoietic stem cell transplantation: risk factors, response to antiviral therapy, and effect on transplant outcome. Blood, 2001, 98, 573-578.	1.4	284
11	Concurrent Trastuzumab and HER2/neu-Specific Vaccination in Patients With Metastatic Breast Cancer. Journal of Clinical Oncology, 2009, 27, 4685-4692.	1.6	277
12	Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy. Blood, 2019, 133, 1652-1663.	1.4	277
13	High HLA-DP Expression and Graft-versus-Host Disease. New England Journal of Medicine, 2015, 373, 599-609.	27.0	264
14	A phase I/II trial of iodine-131â€tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas. Blood, 2000, 96, 2934-2942.	1.4	258
15	Allogeneic hematopoietic stem cell transplantation for myelofibrosis. Blood, 2003, 102, 3912-3918.	1.4	255
16	The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells. Blood, 2019, 133, 1876-1887.	1.4	230
17	Female donors contribute to a selective graft-versus-leukemia effect in male recipients of HLA-matched, related hematopoietic stem cell transplants. Blood, 2004, 103, 347-352.	1.4	225
18	High-dose immunosuppressive therapy and autologous peripheral blood stem cell transplantation for severe multiple sclerosis. Blood, 2003, 102, 2364-2372.	1.4	219

#	ARTICLE	IF	CITATIONS
19	Transfusion-transmitted cytomegalovirus infection after receipt of leukoreduced blood products. <i>Blood</i> , 2003, 101, 4195-4200.	1.4	214
20	Prophylactic administration of imatinib after hematopoietic cell transplantation for high-risk Philadelphia chromosome–positive leukemia. <i>Blood</i> , 2007, 109, 2791-2793.	1.4	210
21	High-dose chemo-radioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma. <i>Blood</i> , 2002, 99, 3158-3162.	1.4	205
22	Infectious morbidity in long-term survivors of allogeneic marrow transplantation is associated with low CD4 T cell counts. <i>American Journal of Hematology</i> , 1997, 54, 131-138.	4.1	203
23	KIR Ligands and Prediction of Relapse after Unrelated Donor Hematopoietic Cell Transplantation for Hematologic Malignancy. <i>Biology of Blood and Marrow Transplantation</i> , 2006, 12, 828-836.	2.0	201
24	High-dose radioimmunotherapy versus conventional high-dose therapy and autologous hematopoietic stem cell transplantation for relapsed follicular non-Hodgkin lymphoma: a multivariable cohort analysis. <i>Blood</i> , 2003, 102, 2351-2357.	1.4	187
25	Hematopoietic Cell Transplantation as Curative Therapy for Idiopathic Myelofibrosis, Advanced Polycythemia Vera, and Essential Thrombocythemia. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 355-365.	2.0	174
26	HLA-matched related hematopoietic cell transplantation for chronic-phase CML using a targeted busulfan and cyclophosphamide preparative regimen. <i>Blood</i> , 2003, 102, 31-35.	1.4	168
27	Allogeneic hematopoietic cell transplantation after conditioning with 131I–anti-CD45 antibody plus fludarabine and low-dose total body irradiation for elderly patients with advanced acute myeloid leukemia or high-risk myelodysplastic syndrome. <i>Blood</i> , 2009, 114, 5444-5453.	1.4	161
28	131I–anti-CD45 antibody plus busulfan and cyclophosphamide before allogeneic hematopoietic cell transplantation for treatment of acute myeloid leukemia in first remission. <i>Blood</i> , 2006, 107, 2184-2191.	1.4	146
29	UTILITY OF TRANSVENOUS LIVER BIOPSIES AND WEDGED HEPATIC VENOUS PRESSURE MEASUREMENTS IN SIXTY MARROW TRANSPLANT RECIPIENTS. <i>Transplantation</i> , 1995, 59, 1015-1022.	1.0	144
30	The significance of bcr-abl molecular detection in chronic myeloid leukemia patients –late, –18 months or more after transplantation. <i>Blood</i> , 2001, 98, 1701-1707.	1.4	137
31	The biological significance of HLA-DP gene variation in haematopoietic cell transplantation. <i>British Journal of Haematology</i> , 2001, 112, 988-994.	2.5	134
32	Veno-occlusive disease of the liver after busulfan, melphalan, and thiotepa conditioning therapy: Incidence, risk factors, and outcome. <i>Biology of Blood and Marrow Transplantation</i> , 1999, 5, 306-315.	2.0	126
33	The effects of imatinib mesylate treatment before allogeneic transplantation for chronic myeloid leukemia. <i>Blood</i> , 2007, 109, 1782-1789.	1.4	126
34	Cutting Edge: Persistent Fetal Microchimerism in T Lymphocytes Is Associated with HLA-DQA1*0501: Implications in Autoimmunity. <i>Journal of Immunology</i> , 2000, 164, 5545-5548.	0.8	125
35	Negative Regulators of Hemopoiesis and Stroma Function in Patients with Myelodysplastic Syndrome. <i>Leukemia and Lymphoma</i> , 2000, 37, 405-414.	1.3	121
36	Ablative Allogeneic Hematopoietic Cell Transplantation in Adults 60 Years of Age and Older. <i>Journal of Clinical Oncology</i> , 2005, 23, 3439-3446.	1.6	120

#	ARTICLE	IF	CITATIONS
37	A randomized, placebo-controlled trial of oral beclomethasone dipropionate as a prednisone-sparing therapy for gastrointestinal graft-versus-host disease. <i>Blood</i> , 2007, 109, 4557-4563.	1.4	115
38	A Retrospective Study of Patients Treated with Imatinib Mesylate Prior to Allogeneic Hematopoietic Stem Cell Transplant.. <i>Blood</i> , 2004, 104, 2752-2752.	1.4	113
39	Normally occurring NKG2D+CD4+ T cells are immunosuppressive and inversely correlated with disease activity in juvenile-onset lupus. <i>Journal of Experimental Medicine</i> , 2009, 206, 793-805.	8.5	105
40	Decreased transfusion requirements for patients receiving nonmyeloablative compared with conventional peripheral blood stem cell transplants from HLA-identical siblings. <i>Blood</i> , 2001, 98, 3584-3588.	1.4	101
41	Association of TLR4 mutations and the risk for acute GVHD after HLA-matched-sibling hematopoietic stem cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2001, 7, 384-387.	2.0	98
42	Nonâ€myeloablative allogeneic haematopoietic cell transplantation for relapsed diffuse large Bâ€cell lymphoma: a multicentre experience. <i>British Journal of Haematology</i> , 2008, 143, 395-403.	2.5	97
43	EASIX in patients with acute graft-versus-host disease: a retrospective cohort analysis. <i>Lancet Haematology</i> , 2017, 4, e414-e423.	4.6	92
44	Non-myeloablative allografting from human leucocyte antigen-identical sibling donors for treatment of acute myeloid leukaemia in first complete remission. <i>British Journal of Haematology</i> , 2003, 120, 281-288.	2.5	90
45	Second allogeneic transplantation after failure of first autologous transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2000, 6, 272-279.	2.0	89
46	ADENOVIRUS NEPHRITIS IN HEMATOPOIETIC STEM-CELL TRANSPLANTATION. <i>Transplantation</i> , 2004, 77, 1049-1057.	1.0	89
47	Cyclophosphamide following Targeted Oral Busulfan as Conditioning for Hematopoietic Cell Transplantation: Pharmacokinetics, Liver Toxicity, and Mortality. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 853-862.	2.0	89
48	Regression of Metastatic Merkel Cell Carcinoma Following Transfer of Polyomavirus-Specific T Cells and Therapies Capable of Reinducing HLA Class-I. <i>Cancer Immunology Research</i> , 2014, 2, 27-36.	3.4	89
49	Pretransplant comorbidities predict severity of acute graft-versus-host disease and subsequent mortality. <i>Blood</i> , 2014, 124, 287-295.	1.4	83
50	Allogeneic Hematopoietic Cell Transplantation for Chronic Myelomonocytic Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2005, 11, 713-720.	2.0	70
51	EASIX and mortality after allogeneic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2020, 55, 553-561.	2.4	70
52	Splenectomy and hemopoietic stem cell transplantation for myelofibrosis. <i>Blood</i> , 2001, 97, 2180-2181.	1.4	64
53	Administration of cyclosporine for 24 months compared with 6 months for prevention of chronic graft-versus-host disease: a prospective randomized clinical trial. <i>Blood</i> , 2001, 98, 3868-3870.	1.4	64
54	Predictors of relapse and overall survival in Philadelphia chromosome[ndash]positive acute lymphoblastic leukemia after transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2003, 9, 206-212.	2.0	64

#	ARTICLE	IF	CITATIONS
55	Immunization of cancer patients with HER-2/neu-derived peptides demonstrating high-affinity binding to multiple class II alleles. <i>Clinical Cancer Research</i> , 2003, 9, 5559-65.	7.0	62
56	High-dose immunosuppressive therapy for severe systemic sclerosis: initial outcomes. <i>Blood</i> , 2002, 100, 1602-10.	1.4	61
57	Evaluation of a CD25-specific immunotoxin for prevention of graft-versus-host disease after unrelated marrow transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2004, 10, 552-560.	2.0	59
58	Single-fraction radiation therapy in patients with metastatic Merkel cell carcinoma. <i>Cancer Medicine</i> , 2015, 4, 1161-1170.	2.8	59
59	MHC-Resident Variation Affects Risks After Unrelated Donor Hematopoietic Cell Transplantation. <i>Science Translational Medicine</i> , 2012, 4, 144ra101.	12.4	55
60	Absence of statistically significant correlation between disparity for the minor histocompatibility antigen HA-1 and outcome after allogeneic hematopoietic cell transplantation. <i>Blood</i> , 2001, 98, 3172-3173.	1.4	53
61	Role of HLA-B exon 1 in graft-versus-host disease after unrelated haemopoietic cell transplantation: a retrospective cohort study. <i>Lancet Haematology</i> , 2020, 7, e50-e60.	4.6	53
62	What Is the Role for Donor Natural Killer Cells after Nonmyeloablative Conditioning?. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 580-588.	2.0	52
63	Astatine-211 conjugated to an anti-CD20 monoclonal antibody eradicates disseminated B-cell lymphoma in a mouse model. <i>Blood</i> , 2015, 125, 2111-2119.	1.4	52
64	Allogeneic haematopoietic cell transplantation for myelofibrosis in 30 patients 60â€“78â€“years of age. <i>British Journal of Haematology</i> , 2011, 153, 76-82.	2.5	51
65	A comparative analysis of conventional and pretargeted radioimmunotherapy of B-cell lymphomas by targeting CD20, CD22, and HLA-DR singly and in combinations. <i>Blood</i> , 2009, 113, 4903-4913.	1.4	50
66	CD38-bispecific antibody pretargeted radioimmunotherapy for multiple myeloma and other B-cell malignancies. <i>Blood</i> , 2018, 131, 611-620.	1.4	49
67	Changing from cyclosporine to tacrolimus as salvage therapy for chronic graft-versus-host disease. <i>Biology of Blood and Marrow Transplantation</i> , 2000, 6, 613-620.	2.0	48
68	HbA1c and Glucose Management Indicator Discordance: A Real-World Analysis. <i>Diabetes Technology and Therapeutics</i> , 2021, 23, 253-258.	4.4	47
69	A Preclinical Model of CD38-Pretargeted Radioimmunotherapy for Plasma Cell Malignancies. <i>Cancer Research</i> , 2014, 74, 1179-1189.	0.9	45
70	Allogeneic haematopoietic cell transplantation after nonmyeloablative conditioning in patients with Tâ€“cell and natural killerâ€“cell lymphomas. <i>British Journal of Haematology</i> , 2010, 150, 170-178.	2.5	44
71	Effect of remission status and induction chemotherapy regimen on outcome of autologous stem cell transplantation for mantle cell lymphoma. <i>Leukemia and Lymphoma</i> , 2008, 49, 1062-1073.	1.3	43
72	Methylenetetrahydrofolate Reductase Genotype Affects Risk of Relapse after Hematopoietic Cell Transplantation for Chronic Myelogenous Leukemia. <i>Clinical Cancer Research</i> , 2004, 10, 7592-7598.	7.0	42

#	ARTICLE	IF	CITATIONS
73	Treatment of chronic myelomonocytic leukaemia by allogeneic marrow transplantation. British Journal of Haematology, 2000, 110, 217-222.	2.5	39
74	Role of HLA-DP Expression in Graft-Versus-Host Disease After Unrelated Donor Transplantation. Journal of Clinical Oncology, 2020, 38, 2712-2718.	1.6	39
75	Peripheral blood stem cell support reduces the toxicity of intensive chemotherapy for children and adolescents with metastatic sarcomas. Cancer, 2002, 95, 1354-1365.	4.1	37
76	Minimal Identifiable Disease and the Role of Conditioning Intensity in Hematopoietic Cell Transplantation for Myelodysplastic Syndrome and Acute Myelogenous Leukemia Evolving from Myelodysplastic Syndrome. Biology of Blood and Marrow Transplantation, 2016, 22, 1227-1233.	2.0	36
77	Are Neurology Residents Prepared to Deal With Dying Patients?. Archives of Neurology, 2009, 66, 1427-8.	4.5	34
78	Estimating GFR in Adult Patients with Hematopoietic Cell Transplant. Clinical Journal of the American Society of Nephrology: CJASN, 2015, 10, 601-610.	4.5	34
79	Hematopoietic Cell Transplantation in Myelodysplastic Syndromes after Treatment with Hypomethylating Agents. Biology of Blood and Marrow Transplantation, 2017, 23, 1509-1514.	2.0	33
80	Changes in Glomerular Filtration Rate and Impact on Long-Term Survival among Adults after Hematopoietic Cell Transplantation. Clinical Journal of the American Society of Nephrology: CJASN, 2018, 13, 866-873.	4.5	33
81	Allografting after nonmyeloablative conditioning as a treatment after a failed conventional hematopoietic cell transplant. Biology of Blood and Marrow Transplantation, 2003, 9, 266-272.	2.0	31
82	Venetoclax Synergizes with Radiotherapy for Treatment of B-cell Lymphomas. Cancer Research, 2017, 77, 3885-3893.	0.9	31
83	Impact of Body Mass Index on Outcomes of Hematopoietic Stem Cell Transplantation in Adults. Biology of Blood and Marrow Transplantation, 2019, 25, 613-620.	2.0	31
84	The β -emitter astatine-211 targeted to CD38 can eradicate multiple myeloma in a disseminated disease model. Blood, 2019, 134, 1247-1256.	1.4	30
85	Correlation of Infused CD3+CD8+ Cells with Single-Donor Dominance after Double-Unit Cord Blood Transplantation. Biology of Blood and Marrow Transplantation, 2013, 19, 156-160.	2.0	28
86	Urinary Elafin and Kidney Injury in Hematopoietic Cell Transplant Recipients. Clinical Journal of the American Society of Nephrology: CJASN, 2015, 10, 12-20.	4.5	28
87	Association of Distance from Transplantation Center and Place of Residence on Outcomes after Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2016, 22, 1319-1323.	2.0	27
88	The use of stereotactic radiosurgery for brain metastases from breast cancer: Who benefits most?. Breast Cancer Research and Treatment, 2015, 149, 743-749.	2.5	26
89	Comparative Analysis of Bispecific Antibody and Streptavidin-Targeted Radioimmunotherapy for B-cell Cancers. Cancer Research, 2016, 76, 6669-6679.	0.9	25
90	The Biologic Significance of Rare Peripheral Blasts After Hematopoietic Cell Transplantation Is Predicted by Multidimensional Flow Cytometry. American Journal of Clinical Pathology, 1999, 112, 513-523.	0.7	24

#	ARTICLE	IF	CITATIONS
91	Employee influenza vaccination in a large cancer center with high baseline compliance rates: Comparison of carrot versus stick approaches. American Journal of Infection Control, 2015, 43, 228-233.	2.3	24
92	High-dose chemotherapy with BEAM or Busulphan/Melphalan and Thiotepa followed by hematopoietic cell transplantation in malignant lymphoma. Leukemia and Lymphoma, 2008, 49, 1899-1906.	1.3	23
93	Azithromycin Use and Increased Cancer Risk among Patients with Bronchiolitis Obliterans after Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2020, 26, 392-400.	2.0	23
94	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IIb. The 2020 Preemptive Therapy Working Group Report. Transplantation and Cellular Therapy, 2021, 27, 632-641.	1.2	21
95	Kinetics of tumor-specific T-cell response development after active immunization in patients with HER-2/neu overexpressing cancers. Clinical Immunology, 2007, 125, 275-280.	3.2	20
96	Relapse after Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndromes: Analysis of Late Relapse Using Comparative Karyotype and Chromosome Genome Array Testing. Biology of Blood and Marrow Transplantation, 2015, 21, 1565-1575.	2.0	20
97	HLA-B Leader and Survivorship after HLA-Mismatched Unrelated Donor Transplantation. Blood, 2020, 136, 362-369.	1.4	20
98	Curative Therapy of Advanced Essential Thrombocythemia or Polycythemia Vera by Hemopoietic Stem Cell Transplantation. Leukemia and Lymphoma, 2002, 43, 1409-1414.	1.3	19
99	Early Post-Transplantation Spirometry Is Associated with the Development of Bronchiolitis Obliterans Syndrome after Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2020, 26, 943-948.	2.0	19
100	131I-Anti-CD45 Antibody Plus Fludarabine, Low-Dose Total Body Irradiation and Peripheral Blood Stem Cell Infusion for Elderly Patients with Advanced Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS).. Blood, 2005, 106, 397-397.	1.4	19
101	Posttransplant feasibility study of nilotinib prophylaxis for high-risk Philadelphia chromosome positive leukemia. Blood, 2017, 130, 1170-1172.	1.4	18
102	A Phase I/II Study of Chemotherapy Followed by Donor Lymphocyte Infusion plus Interleukin-2 for Relapsed Acute Leukemia after Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2011, 17, 1308-1315.	2.0	17
103	Paper or plastic? BCR-ABL1 quantitation and mutation detection from dried blood spots. Blood, 2016, 127, 2773-2774.	1.4	17
104	Tumor Necrosis Factor Polymorphism Affects Transplantation Outcome in Patients with Myelodysplastic Syndrome but Not in Those with Chronic Myelogenous Leukemia, Independent of the Presence of HLA-DR15. Biology of Blood and Marrow Transplantation, 2010, 16, 1700-1706.	2.0	15
105	Gene expression patterns in myelodysplasia underline the role of apoptosis and differentiation in disease initiation and progression. Translational Oncogenomics, 2008, 3, 137-49.	1.7	13
106	No telomere shortening in marrow stroma from patients with MDS. Annals of Hematology, 2009, 88, 623-628.	1.8	12
107	Use of the HLA-B leader to optimize cord blood transplantation. Haematologica, 2021, 106, 3107-3114.	3.5	12
108	High-dose CD20-targeted radioimmunotherapy-based autologous transplantation improves outcomes for persistent mantle cell lymphoma. British Journal of Haematology, 2015, 171, 788-797.	2.5	11

#	ARTICLE	IF	CITATIONS
109	Increased prevalence of CMV gB3 in marrow of patients with aplastic anemia. <i>Blood</i> , 2001, 98, 891-892.	1.4	10
110	Outcomes of Patients with Large B-Cell Lymphomas and Progressive Disease Following CD19-Specific CAR T-Cell Therapy. <i>Blood</i> , 2018, 132, 94-94.	1.4	10
111	Pre-transplant comorbidity burden and post-transplant chronic graft-versus-host disease. <i>British Journal of Haematology</i> , 2015, 171, 411-416.	2.5	9
112	HLA mismatches and hematopoietic cell transplantation: structural simulations assess the impact of changes in pep-tide binding specificity on transplant outcome. <i>Immunome Research</i> , 2011, 7, 4.	0.1	9
113	Favorable Outcome of Patients with Relapsed Hodgkin Lymphoma (HL) after Nonmyeloablative Hematopoietic Cell Transplantation (NM-HCT) Using Related Haploidentical Donors.. <i>Blood</i> , 2006, 108, 3135-3135.	1.4	9
114	A phase II trial evaluating the efficacy of high-dose Radioiodinated Tositumomab (Anti-CD20) antibody, etoposide and cyclophosphamide followed by autologous transplantation, for high-risk relapsed or refractory non-Hodgkin lymphoma. <i>American Journal of Hematology</i> , 2020, 95, 775-783.	4.1	7
115	Respiratory Syncytial Virus (RSV) Infection in Hematopoietic Stem Cell Transplant (HCT) Recipients: Risk Factors for Acquisition and Lower Respiratory Tract Disease, and Impact on Mortality.. <i>Blood</i> , 2004, 104, 187-187.	1.4	7
116	90Y-labeled anti-CD45 antibody allogeneic hematopoietic cell transplantation for high-risk multiple myeloma. <i>Bone Marrow Transplantation</i> , 2021, 56, 202-209.	2.4	6
117	Safety and Efficacy of Yttrium-90-Labeled Anti-CD45 Antibody (90Y-DOTA-BC8) Followed By a Standard Reduced-Intensity Hematopoietic Stem Cell Transplant (HCT) Regimen for Patients with Refractory/Relapsed Leukemia or High-Risk Myelodysplastic Syndrome (MDS). <i>Blood</i> , 2018, 132, 1018-1018.	1.4	6
118	Reduced Relapse and Similar Progression-Free Survival After Double Umbilical Cord Blood Transplantation (DUCBT): Comparison of Outcomes Between Sibling, Unrelated Adult and Unrelated DUCB Hematopoietic Stem Cell (HSC) Donors.. <i>Blood</i> , 2009, 114, 662-662.	1.4	5
119	A Phase I Trial of 90Y-BC8-DOTA (Anti-CD45) Monoclonal Antibody in Combination with Fludarabine and TBI As Conditioning for Allogeneic Peripheral Blood Stem Cell Transplant to Treat High Risk Multiple Myeloma. <i>Blood</i> , 2017, 130, 910-910.	1.4	5
120	Proliferation-Linked Apoptosis of Adoptively Transferred T Cells after IL-15 Administration in Macaques. <i>PLoS ONE</i> , 2013, 8, e56268.	2.5	4
121	Outcome Following Hematopoietic Cell Transplantation for Patients with AML-CR1: Comparison between Matched-Sibling and Unrelated Allografts.. <i>Blood</i> , 2007, 110, 330-330.	1.4	4
122	Impact of Pre-Transplant Minimal Residual Disease Assessed by Flow Cytometry on Outcome Following Myeloablative Hematopoietic Cell Transplantation for Patients with AML-CR1.. <i>Blood</i> , 2008, 112, 3253-3253.	1.4	4
123	131I-tositumomab myeloablative radioimmunotherapy for non-Hodgkin's lymphoma. <i>Nuclear Medicine Communications</i> , 2012, 33, 1225-1231.	1.1	3
124	A pilot study of weekly brentuximab vedotin in patients with CD30+ malignancies resistant to brentuximab vedotin every 3 weeks. <i>British Journal of Haematology</i> , 2019, 186, 159-162.	2.5	3
125	Impact of the Novel 5-Group Cytogenetic Risk Classification of MDS on Outcome After Allogeneic Hematopoietic Cell Transplantation (HCT). <i>Blood</i> , 2011, 118, 666-666.	1.4	3
126	Pre-Transplant Expressions of Micrnas Are Associated with Both Comorbidity Burden and Mortality Risks in Patients (Pts) with Acute Leukemia (AL) in Complete Remission (CR) Given Allogeneic Hematopoietic Cell Transplantation (HCT). <i>Blood</i> , 2015, 126, 385-385.	1.4	3

#	ARTICLE	IF	CITATIONS
127	Umbilical Cord Blood Transplantation in Patients with Hematological Malignancies Using a Non-ATG Containing Reduced Intensity Preparative Regimen. Blood, 2011, 118, 1943-1943.	1.4	3
128	Long Term Follow-up of High-Dose CD20-Targeted Radioimmunotherapy-Based Autologous Transplantation for Patients with Mantle Cell Lymphoma. Blood, 2014, 124, 3967-3967.	1.4	3
129	Low Achievement of End of Life Quality Measures in Large B-Cell Lymphoma Patients Who Progressed after CD19-Specific CAR-T Cell Therapy. Blood, 2019, 134, 413-413.	1.4	2
130	131I-Anti-CD45 Antibody Plus Busulfan/Cyclophosphamide in Matched Related Transplants for Acute Myeloid Leukemia in First Remission.. Blood, 2004, 104, 813-813.	1.4	2
131	What Is the Role for Donor NK Cells after Nonmyeloablative Conditioning?. Blood, 2007, 110, 476-476.	1.4	2
132	Long-Term Follow up of a Comparison of Non-Myeloablative Allografting with Autografting for Newly Diagnosed Myeloma. Blood, 2010, 116, 525-525.	1.4	2
133	Effect of Peripheral Blood Stem Cell (PBSC) Graft Composition on Graft Versus Host Disease (GVHD) and Mortality After Allogeneic Transplantation. Blood, 2010, 116, 676-676.	1.4	2
134	A Phase I Study Of Myeloablative Radioimmunotherapy Using Iodine-131 Anti-CD45 Antibody Followed By Autologous Stem Cell Transplantation For High-Risk B-Cell and T-Cell Non-Hodgkin Lymphoma and Hodgkin Lymphoma. Blood, 2013, 122, 3333-3333.	1.4	2
135	Anti-CD38 Pretargeted Radioimmunotherapy Eradicates Multiple Myeloma Xenografts In a Murine Model. Blood, 2013, 122, 882-882.	1.4	2
136	Higher Doses of Transplanted T and B Cells Are Associated with Greater Incidence of Extensive Chronic GVHD after PBSC Transplantation from HLA-Identical Sibling Donors.. Blood, 2007, 110, 1077-1077.	1.4	2
137	A Phase I Study of Myeloablative I-131-Anti CD-20 (Tositumomab) Radioimmunotherapy with Escalating Doses of Fludarabine Followed by Autologous Hematopoietic Stem Cell Transplantation (ASCT) for Adults ≥ 60 Years of Age with High-Risk or Relapsed/Refractory B-Cell Lymphoma. Blood, 2011, 118, 663-663.	1.4	2
138	Reply. Journal of Infectious Diseases, 1999, 180, 572-574.	4.0	1
139	Factors Impacting Progression-Free Survival after CD19-Specific CAR-T Cell Therapy for Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma. Blood, 2018, 132, 1681-1681.	1.4	1
140	Ixazomib in Previously Untreated Indolent B-Cell Non-Hodgkin Lymphoma. Blood, 2018, 132, 5326-5326.	1.4	1
141	Preferentially Expressed Antigen in Melanoma (PRAME) Expression in Normal and CML CD34+ Progenitor Cells Impairs Myeloid Differentiation.. Blood, 2008, 112, 1071-1071.	1.4	1
142	Genetic Allelic Variation in the p53 DNA Repair Pathway Constitute a Risk Factor for Long-Term Survival in Hematopoietic Stem Cell Transplantation. Blood, 2008, 112, 337-337.	1.4	1
143	A Phase I Study of Vorinostat (V) in Combination with Rituximab (R), Ifosphamide, Carboplatin, and Etoposide (ICE) for Patients with Relapsed or Refractory Lymphoid Malignancies or Untreated T- or Mantle Cell Lymphoma.. Blood, 2009, 114, 3696-3696.	1.4	1
144	Differential Gene Expression Associated with Chronic Myeloid Leukemia (CML) Progression Predicts Relapse and Survival Prior to Allogeneic Transplantation In Chronic Phase CML Patients. Blood, 2010, 116, 3507-3507.	1.4	1

#	ARTICLE	IF	CITATIONS
145	Anti-CD38 Pretargeted Radioimmunotherapy Demonstrates Therapeutic Efficacy In a Human Multiple Myeloma Mouse Xenograft Model. <i>Blood</i> , 2011, 118, 1842-1842.	1.4	1
146	Influence of Infused Naïve CD3+CD8+ and CD3+CD56+ NKT-Cells on Single Unit Dominance After Double Cord Blood Transplantation. <i>Blood</i> , 2011, 118, 652-652.	1.4	1
147	Bendamustine (Treanda®), Etoposide and Dexamethasone (BED) Followed by GCSF Effectively Mobilizes Autologous Peripheral Blood Hematopoietic Stem Cells. <i>Blood</i> , 2012, 120, 4126-4126.	1.4	1
148	Non-Myeloablative Allografting from HLA-Identical Sibling Donors for Treatment of CML. <i>Blood</i> , 2004, 104, 2316-2316.	1.4	1
149	Outcomes of Early Relapse Following Non-Myeloablative Allogeneic Transplant for Lymphoma. <i>Blood</i> , 2009, 114, 1204-1204.	1.4	1
150	Re: An Approach to Predicting HSCT Outcome Using HLA-Mismatch Information Mapped on Protein Structure Data. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 865-866.	2.0	0
151	Bendamustine, etoposide, and dexamethasone to mobilize peripheral blood hematopoietic stem cells for autologous transplantation in non-Hodgkin lymphoma. <i>Blood Research</i> , 2018, 53, 223.	1.3	0
152	The Follicular Lymphoma International Prognostic Index (FLIPI) as Part of a Proposed Prognostic Model for Follicular Lymphoma Patients Undergoing Autologous Hematopoietic Stem Cell Transplantation (ASCT). <i>Blood</i> , 2004, 104, 12-12.	1.4	0
153	Four-Year Follow-Up after High-Dose Immunosuppressive Therapy (HDIT) for Severe Systemic Sclerosis (SSc). <i>Blood</i> , 2006, 108, 3071-3071.	1.4	0
154	Outcomes after Autologous Stem Cell Transplantation for Mantle Cell Lymphoma Based on Remission Status and Induction Chemotherapy Regimen. <i>Blood</i> , 2007, 110, 1905-1905.	1.4	0
155	A Prospective Multicenter Phase II Study by the Puget Sound Oncology Consortium (PSOC) of Gemcitabine (G), Carboplatin (C), Dexamethasone (D), and Rituximab (R) in Patients with Relapsed/Refractory Lymphoma. <i>Blood</i> , 2008, 112, 2585-2585.	1.4	0
156	Pulse High-Dose Vorinostat Can Be Delivered with Rituximab, Ifosphamide, Carboplatin, and Etoposide In Patients with Relapsed Lymphoma: Final Results of a Phase I Trial. <i>Blood</i> , 2010, 116, 2790-2790.	1.4	0
157	Conventional Anti-CD45 Radioimmunotherapy Comparing 90Y or 177Lu for Treatment of AML in a Syngeneic Disseminated Murine Leukemia Model. <i>Blood</i> , 2011, 118, 3636-3636.	1.4	0
158	Characterization of Chronic Graft-Versus-Host Disease and Duration of Immunosuppression After Cord Blood Transplantation. <i>Blood</i> , 2011, 118, 4077-4077.	1.4	0
159	Myeloablative Umbilical Cord Blood Transplantation for Hematologic Malignancies Is Comparable to Unrelated Donor Transplantation: A Retrospective Single-Center Study. <i>Blood</i> , 2012, 120, 1995-1995.	1.4	0
160	Bendamustine (Treanda®)-Based Regimens Are Effective In Mobilizing Peripheral Blood Hematopoietic Stem Cells For Autologous Transplantation. <i>Blood</i> , 2013, 122, 2033-2033.	1.4	0
161	A Phase II Trial of Radioimmunotherapy-Based Autologous Transplantation with I-131 Tositumomab, Cyclophosphamide and Etoposide in Relapsed/Refractory Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2015, 126, 5502-5502.	1.4	0
162	Post-Hematopoietic Stem Cell Transplantation Minimal Residual Disease and Early Relapses in MDS and AML Evolving from MDS. <i>Blood</i> , 2015, 126, 2019-2019.	1.4	0

#	ARTICLE	IF	CITATIONS
163	Multivariable Modeling of Disease and Treatment Characteristics of Adults with B-ALL in MRD-Negative CR after CD19 CAR-T Cells Identifies Factors Impacting Disease-Free Survival. Blood, 2018, 132, 281-281.	1.4	0
164	Impact of Lab Abnormalities at the Time of Progression in Patients Receiving CD19-Specific CAR T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphomas. Blood, 2019, 134, 2889-2889.	1.4	0